The last week of August proved to be a relatively significant one for multiple med-tech companies. Although the Labor Day holiday is likely to keep a lid on the news flow in the first week of September, there are a few upcoming earnings reports. What's more, the timing of restructurings, acquisitions and the like are inherently unpredictable and I would not be surprised to hear more news along these lines.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Helicos Looks Like It's Out of Moves
Few readers are going to be familiar with Helicos BioSciences (OTC:HLCS), as this tiny life sciences company has failed to successfully commercialize its direct DNA and RNA molecule sequencing technology. Although the technology is legitimately interesting, the company's execution mistakes left it with basically a long-shot survival strategy - suing other, larger, life science companies like Pacific Biosciences (Nasdaq:PACB), Life Technologies (Nasdaq:LIFE) and Illumina (Nasdaq:ILMN) for patent infringement.

Unfortunately for Helicos shareholders, the company may well have just lost the last hand in the game. The company dropped its litigation with Life Tech and settled with PacBio in May, but there has been nothing in Helicos' SEC filings to suggest that the settlement was financially meaningful. Worse still, the company saw a judge render a summary judgment invalidating the remaining patent in question against Illumina. At this point, the best remaining hope for Helicos is that a larger life sciences company is willing to pay something for its IP and technology, but investors should not expect to see any significant benefit from such an outcome.

SEE: Investing In The Healthcare Sector

Two More Companies Hope to Find Better Margins Through Restructuring
Two out of the three players in the North American cardiac rhythm management market (that is pacemakers and ICDs) have apparently launched restructurings. The news that Boston Scientific (NYSE:BSX) is doing so again scarcely qualifies as news, as this company has been in seemingly perpetual restructuring/turnaround for years. Nevertheless, the company will apparently still cut more jobs and separate its two main cardiovascular businesses (after combining them a while back).

The news of a restructuring at St. Jude Medical (NYSE:STJ) is a little more surprising, as this company has been doing relatively better despite a weak CRM market. St. Jude will reportedly be firing 300 people and reorganizing its business into two operating units focused on implantable electronic devices and cardiovascular/ablation technology.

SEE: Cashing In On Corporate Restructuring

AstraZeneca Makes a Good Hire
AstraZeneca
(NYSE:AZN) has been a struggling Big Pharma for some time now, as patent expirations and pipeline failures have left the company's revenue situation in poor shape. In recent months the company has been an active acquirer and partner - tying up with Amgen (Nasdaq:AMGN), buying Ardea and sharing in Bristol-Myers' (NYSE:BMY) purchase of Amylin.

Now the company has a new leader as well. AstraZeneca has tapped Pascal Soriot as the new CEO. Soriot is the former CEO of Genentech and has served as Roche's (OTC:RHHBY) Chief Operating Officer of the pharmaceutical division since the acquisition of Genentech. This is an excellent hire for AstraZeneca, given Soriot's demonstrated ability in overseeing successful pipeline development and product launches for many years now. While this is a loss for Roche, it's not altogether unexpected and the company has a deep bench of managerial talent.

SEE: 6 Great Companies With Top-Notch Healthcare Benefits

The Bottom Line
Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally. For what it's worth, it's not uncommon for healthcare stocks to "drift" in the late summer. The Health Care Select Sector SPDR (ARCA:XLV) is up about 12% year-to-date, below the the 12.8% return of the S&P 500. The iShares Dow Jones US Pharmaceuticals ETF (ARCA:IHE) is up about 14%, while the iShares Dow Jones US Medical Devices ETF (ARCA:IHI) is up almost 12%. The SPDR Biotech ETF (ARCA:XBI) continues its tear, having risen almost 35% year-to-date.

At the time of writing, Stephen D. Simpson owned shares of Roche, and has since 2011.

Related Articles
  1. Forex Education

    China's Devaluation of the Yuan

    Just over one week ago the People’s Bank of China (PBOC) surprised markets with three consecutive devaluations of the yuan, knocking over 3% off its value.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI Europe Financials

    Learn about the iShares MSCI Europe Financials fund, which invests in numerous European financial industries, such as banks, insurance and real estate.
  5. Mutual Funds & ETFs

    ETF Analysis: SPDR S&P Insurance

    Learn about the SPDR S&P Insurance exchange-traded fund, which follows the S&P Insurance Select Industry Index by investing in equities of U.S. insurers.
  6. Mutual Funds & ETFs

    ETF Analysis: SPDR S&P Emerging Markets Small Cap

    Learn about the SPDR S&P Emerging Markets Small Cap exchange-traded fund, which invests in small-cap firms traded at the emerging equity markets.
  7. Mutual Funds & ETFs

    ETF Analysis: ETFS Physical Platinum

    Learn about the physical platinum ETF. Platinum embarked on a bull market from 2001 to 2011, climbing to record prices along with other precious metals.
  8. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI Turkey

    Learn about the iShares MSCI Turkey exchange-traded fund, which invests in a wide variety of companies' equities traded on Turkish exchanges.
  9. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  10. Mutual Funds & ETFs

    ETF Analysis: Guggenheim Enhanced Short Dur

    Find out about the Guggenheim Enhanced Short Duration ETF, and learn detailed information about this fund that focuses on fixed-income securities.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Exchange-Traded Fund (ETF)

    A security that tracks an index, a commodity or a basket of assets ...
  3. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  4. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  5. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  6. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
RELATED FAQS
  1. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>
  6. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!